4 ms·

SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801 (In mice)

23 points by MKais 6y ago

sschueller 6y ago
"In April 2020, a whistleblower complaint by former Head of US Biomedical Advanced Research and Development Authority (BARDA) Rick Bright revealed concerns over providing funding for the further development of molnupiravir due to similar drugs having mutagenic properties (producing birth defects).[4] A previous company, Pharmasset, that had investigated the drug's active ingredient had abandoned it. These claims were denied by George Painter, CEO of DRIVE, noting that toxicity studies on molnupiravir had been carried out and data provided to regulators in the US and UK, who permitted safety studies in humans to move forward in the spring of 2020. Also at this time, DRIVE and Ridgeback Biotherapeutics stated they planned future safety studies in animals.[5]" https://en.m.wikipedia.org/wiki/Molnupiravir https://en.m.wikipedia.org/wiki/Molnupiravir
- core-questions 6y ago
  Birth defects are a big deal, but there is a decent portion of the population who aren't going to be giving birth (at all, or ever again) who could still probably benefit...
collyw 6y ago
Hydroxychloroquine seems to have decent results as well (though with side effects) according to the most recent meta analyses. But Trump suggested it, so it needed to be banned despite decades of safe use. https://medium.com/microbial-instincts/the-verdict-of-3-new-meta-analyses-on-hydroxychloroquine-for-covid-19-40cfa9381e9a https://medium.com/microbial-instincts/the-verdict-of-3-new-...
- Uberphallus 6y ago
  > Hydroxychloroquine seems to have decent results as well (though with side effects) according to the most recent meta analyses. From link: > In conclusion, this meta-analysis clearly shows that HCQ alone is not effective for the treatment of Covid-19 patients and that the combination of HCQ and AZI increases the risk of mortality. > Failure of HCQ to show viral clearance or clinical benefits with additional adverse effects outweigh its protective effect from radiological progression in non-severe Covid-19 patients. > HCQ is associated with more total AEs [adverse effects], gastrointestinal AEs, and skin and subcutaneous tissue AEs compared with placebo or no intervention in the overall population If by decent result you mean "it certainly does something but it's not even clear if it's good or bad", then sure, it's decent. HCQ is still being studied as it might be useful it some particular scenarios, but its general use is discouraged and understandably so.
- sradman 6y ago
  TWiV #715 @3m14s [1] discusses the paper Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated by TMPRSS2 [2], including the wonderful Figure 1. TL;DR: Hydroxychloroquine worked in the lab with cells that have ACE2 but lacked TMPRSS2. Human trials failed because SARS-CoV-2 can enter the cell via a 2nd pathway assisted by TMPRSS2. Hydroxychloroquine probably works in combination with Camostat. [1] https://youtu.be/l-YyM-0CHZU?t=3m14s https://youtu.be/l-YyM-0CHZU?t=3m14s [2] https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1009212 https://journals.plos.org/plospathogens/article?id=10.1371/j...
sradman 6y ago
The paper SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801 [1] comes out of Ralph Baric's lab: > Here we used a single experimental platform based on human lung-only mice (LoM) to demonstrate efficient in vivo replication of all recently emerged human coronaviruses (SARS-CoV, MERS-CoV and SARS-CoV-2) and two highly relevant endogenous pre-pandemic SARS-like bat coronaviruses. > Our results show that therapeutic and prophylactic administration of EIDD-2801, an oral broad spectrum antiviral currently in phase II–III clinical trials, dramatically inhibited SARS-CoV-2 replication in vivo and thus has significant potential for the prevention and treatment of COVID-19. EIDD-2801 (Molnupiravir [2]) is an oral antiviral while monoclonal antibody treatment requires intravenous delivery. [1] https://www.nature.com/articles/s41586-021-03312-w https://www.nature.com/articles/s41586-021-03312-w [2] https://en.wikipedia.org/wiki/Molnupiravir https://en.wikipedia.org/wiki/Molnupiravir

23 points by MKais 6y ago

"In April 2020, a whistleblower complaint by former Head of US Biomedical Advanced Research and Development Authority (BARDA) Rick Bright revealed concerns over providing funding for the further development of molnupiravir due to similar drugs having mutagenic properties (producing birth defects).[4] A previous company, Pharmasset, that had investigated the drug's active ingredient had abandoned it. These claims were denied by George Painter, CEO of DRIVE, noting that toxicity studies on molnupiravir had been carried out and data provided to regulators in the US and UK, who permitted safety studies in humans to move forward in the spring of 2020. Also at this time, DRIVE and Ridgeback Biotherapeutics stated they planned future safety studies in animals.[5]" https://en.m.wikipedia.org/wiki/Molnupiravir https://en.m.wikipedia.org/wiki/Molnupiravir

core-questions 6y ago
Birth defects are a big deal, but there is a decent portion of the population who aren't going to be giving birth (at all, or ever again) who could still probably benefit...

collyw 6y ago

Hydroxychloroquine seems to have decent results as well (though with side effects) according to the most recent meta analyses. But Trump suggested it, so it needed to be banned despite decades of safe use. https://medium.com/microbial-instincts/the-verdict-of-3-new-meta-analyses-on-hydroxychloroquine-for-covid-19-40cfa9381e9a https://medium.com/microbial-instincts/the-verdict-of-3-new-...

Uberphallus 6y ago
> Hydroxychloroquine seems to have decent results as well (though with side effects) according to the most recent meta analyses. From link: > In conclusion, this meta-analysis clearly shows that HCQ alone is not effective for the treatment of Covid-19 patients and that the combination of HCQ and AZI increases the risk of mortality. > Failure of HCQ to show viral clearance or clinical benefits with additional adverse effects outweigh its protective effect from radiological progression in non-severe Covid-19 patients. > HCQ is associated with more total AEs [adverse effects], gastrointestinal AEs, and skin and subcutaneous tissue AEs compared with placebo or no intervention in the overall population If by decent result you mean "it certainly does something but it's not even clear if it's good or bad", then sure, it's decent. HCQ is still being studied as it might be useful it some particular scenarios, but its general use is discouraged and understandably so.
sradman 6y ago
TWiV #715 @3m14s [1] discusses the paper Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated by TMPRSS2 [2], including the wonderful Figure 1. TL;DR: Hydroxychloroquine worked in the lab with cells that have ACE2 but lacked TMPRSS2. Human trials failed because SARS-CoV-2 can enter the cell via a 2nd pathway assisted by TMPRSS2. Hydroxychloroquine probably works in combination with Camostat. [1] https://youtu.be/l-YyM-0CHZU?t=3m14s https://youtu.be/l-YyM-0CHZU?t=3m14s [2] https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1009212 https://journals.plos.org/plospathogens/article?id=10.1371/j...

sradman 6y ago

The paper SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801 [1] comes out of Ralph Baric's lab: > Here we used a single experimental platform based on human lung-only mice (LoM) to demonstrate efficient in vivo replication of all recently emerged human coronaviruses (SARS-CoV, MERS-CoV and SARS-CoV-2) and two highly relevant endogenous pre-pandemic SARS-like bat coronaviruses. > Our results show that therapeutic and prophylactic administration of EIDD-2801, an oral broad spectrum antiviral currently in phase II–III clinical trials, dramatically inhibited SARS-CoV-2 replication in vivo and thus has significant potential for the prevention and treatment of COVID-19. EIDD-2801 (Molnupiravir [2]) is an oral antiviral while monoclonal antibody treatment requires intravenous delivery. [1] https://www.nature.com/articles/s41586-021-03312-w https://www.nature.com/articles/s41586-021-03312-w [2] https://en.wikipedia.org/wiki/Molnupiravir https://en.wikipedia.org/wiki/Molnupiravir